R&D 5 changes underway for R&D IT shifting to advanced modalitie... Back in 2000, the FDA approved only six biologics versus 27 new molecular entities (NMEs).
Patients Providing patient access to new therapies, with Dean Erhardt Dean Erhardt, founder of D2 Solutions, discusses patient access today versus the state of patient access tomorrow.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
